Kaimann has been sold to Saint-Gobain
Lincoln acted as the exclusive financial advisor to the seller, managing a highly competitive M&A process with strong interest from multiple international strategic as well as financial investors.
Kaimann, headquartered in Hövelhof, Germany, is the engineering and innovation leader for flexible elastomeric foams. Kaimann is renowned for its comprehensive portfolio of elastomeric foam solutions, ensuring high efficiency as well as safe and effective fire, noise and corrosion protection for thermal insulation as well as systems covering, special and non-insulation applications. Kaimann operates with subsidiaries in France, Italy, Poland, Russia, Spain and the UK. Founded in 1959, Kaimann employs 320 people and achieved sales of Euro 70 million in 2017.
Saint-Gobain is a producer and distributor of a variety of construction and high-performance materials used in buildings, transportation, infrastructure and in many industrial applications. Saint-Gobain operates in 67 countries with more than 179,000 employees and achieved sales of Euro 40.8 billion in 2017.
Georg Josef (Jürgen) Kaimann, CEO of Kaimann, commented: “We are very pleased by the result of this transaction. The combination with Saint-Gobain will allow Kaimann to make the most of its manifold growth potentials including international expansion and entering into new product segments.”
Meet our Senior Team
View More Transactions
Lincoln International is pleased to announce the successful sale of C³ (Cannabinoid Compound Company), a subsidiary of Bionorica SE, a producer and marketer of cannabis-based therapeutic compounds, to Canopy Growth
Lincoln is pleased to announce that it has advised Riello Investimenti SGR on the sale of Trafimet Group to Kemppi Oy
Lincoln International is pleased to have advised Tikehau Capital on its £23 million minority investment into Medtrade, a UK based manufacturer of advanced woundcare and consumer healthcare products
Lincoln International is pleased to announce the successful completion of a $20 million Series C financing round for Rapid Medical